PMH9 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM

Nov 1, 2004, 00:00 AM
10.1016/S1098-3015(10)66079-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)66079-2/fulltext
Section Title :
Section Order : 446
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66079-2&doi=10.1016/S1098-3015(10)66079-2
HEOR Topics :
Tags :
Regions :